Autolus Therapeutics (AUTL) announces pivotal Phase 2 FELIX clinical trial has met primary endpoint at interim analysis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/31/2026

1. WDAY
2. ESTC
3. MRVL
4. AFRM
5. RBRK
6. S
7. ULTA
8. NVDA
9. GAP
10. DG

Go back to Autolus Therapeutics (AUTL) announces pivotal Phase 2 FELIX clinical trial has met primary endpoint at interim analysis

Autolus Therapeutics announces pivotal Phase 2 FELIX clinical trial has met primary endpoint at interim analysis

December 8, 2022 4:01 PM EST

Obe-cel demonstrated Overall Remission Rate (ORR) of 70% in interim analysis of 50 patients with relapsed/refractory (r/r) adult Acute Lymphoblastic Leukemia (ALL)Encouraging safety data observed, with 3% Grade 3 Cytokine Release Syndrome (CRS) and 8% Grade 3 Immune effector cell-associated neurotoxicity syndrome (ICANS) in 92 patients treated Achievement of development milestone has triggered payment of $35m from Blackstone Life Sciences, announced in a separate press release todayThe trial has completed screening patients for entry into the morphological cohort

LONDON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq:... More